| mRNA |
YL54 |
CTRPv2 |
pan-cancer |
AAC |
0.0032 |
0.9 |
| mRNA |
OSI-930 |
CTRPv2 |
pan-cancer |
AAC |
-0.0029 |
0.9 |
| mRNA |
Sorafenib |
CCLE |
pan-cancer |
AAC |
-0.0039 |
0.9 |
| mRNA |
dacarbazine |
CTRPv2 |
pan-cancer |
AAC |
-0.0025 |
0.9 |
| mRNA |
etomoxir |
CTRPv2 |
pan-cancer |
AAC |
-0.0029 |
0.9 |
| mRNA |
MI-2 |
CTRPv2 |
pan-cancer |
AAC |
0.0041 |
0.9 |
| mRNA |
Camptothecin |
GDSC1000 |
pan-cancer |
AAC |
0.0027 |
0.9 |
| mRNA |
BRD-K96970199 |
CTRPv2 |
pan-cancer |
AAC |
0.0055 |
0.9 |
| mRNA |
BRD-A02303741:navitoclax (2:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
0.0026 |
0.9 |
| mRNA |
docetaxel:tanespimycin (2:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
-0.0024 |
0.9 |